KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Leases (2019)

Johnson & Johnson recorded quarterly Leases of $957.0 million in Q4 2019, down 0.62% quarter-over-quarter from $963.0 million in Q3 2019.

Johnson & Johnson's Leases history runs 1 years deep, the most recent figure standing at $957.0 million for Q4 2019.

  • In Q4 2019, Leases changed N/A year-over-year to $957.0 million; the TTM figure through Dec 2019 stood at $957.0 million (changed N/A YoY), while the FY2019 annual figure was $957.0 million, changed N/A from the prior year.
  • Leases came in at $957.0 million for Q4 2019 at Johnson & Johnson, down from $963.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $980.0 million in Q2 2019 to a low of $879.0 million in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 1.53 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 29, 2019 957.00 Mn
Sep 29, 2019 963.00 Mn
Jun 30, 2019 980.00 Mn
Mar 31, 2019 879.00 Mn